8-K: Semnur Completes Merger, Secures $100M Bitcoin Investment

Semnur Pharmaceuticals, Inc. finalized its business combination, becoming a public entity and announcing a significant $100 million equity investment paid in Bitcoin.

Summary

• Semnur Pharmaceuticals, Inc. (formerly Denali Capital Acquisition Corp.) completed its business combination with Legacy Semnur on September 22, 2025, and will operate as New Semnur.
• New Semnur's common stock and warrants began trading on the OTC Markets under symbols SMNR and SMNRW, respectively, on September 23, 2025.
• Scilex Holding Company (SHC) now owns approximately 87.5% of New Semnur's common stock post-Business Combination.
• A Securities Purchase Agreement (SPA) was signed with Biconomy PTE.LTD for the purchase of 6,250,000 shares of New Semnur Common Stock at $16.00 per share, totaling $100 million, payable in Bitcoin.
• Biconomy.com has been engaged to collaborate on future cryptocurrency strategies, including reserve build-up and treasury management.
• An existing $54,236,058 intercompany indebtedness owed by Legacy Semnur to SHC was converted into 5,423,606 shares of New Semnur Series A Preferred Stock and 542,361 shares of New Semnur Common Stock.
• Promissory notes totaling $1,325,000 each were issued to D. Boral Capital, LLC and U.S. Tiger Securities, Inc., payable in nine monthly installments of $150,000 starting October 1, 2025, with acceleration clauses upon future financing.
• A promissory note for $806,366.78 was issued to Denali Capital Global Investments LLC (Sponsor), payable in six monthly installments starting October 1, 2025, also with an acceleration clause.
• A promissory note for $1,022,228.49 was issued to FutureTech Capital LLC, payable in six monthly installments of $170,371.42 starting October 1, 2025, with an acceleration clause.
• The closing of a previously announced PIPE SPA for 1,250,000 shares ($20.0 million) was amended to occur no later than the 14th business day following the Business Combination closing.

Sentiment

Score: 5

Explanation: While the completion of the business combination and the significant capital infusion are positive for the company's liquidity and continued drug development, the highly unconventional and speculative nature of the Bitcoin-based investment and treasury strategy introduces substantial new risks and uncertainties for a pharmaceutical company. The ongoing accumulated deficit and going concern warning also temper overall sentiment.

Positives

• Successfully completed the business combination, transitioning to a public company and gaining access to public capital markets.
• Secured a significant $100 million equity investment through the Biconomy SPA, providing crucial capital for operations and growth.
• Converted over $54 million in related party debt into preferred and common equity, strengthening the balance sheet by reducing liabilities.
• The lead product candidate, SP-102 (SEMDEXA), a non-opioid pain therapy, has completed a pivotal Phase 3 study with positive results (achievement of primary and secondary endpoints) and was granted Fast Track status by the FDA in 2017.
• New management team and board of directors appointed, bringing leadership for the combined entity.

Negatives

• Reported a net loss of $1.7 million for the six months ended June 30, 2025, and an accumulated deficit of $117.0 million, indicating ongoing operational losses.
• The company had only $55,000 in cash and cash equivalents as of June 30, 2025, highlighting a critical need for external financing.
• Management has concluded that conditions raise substantial doubt about the company's ability to continue as a going concern for one year after the financial statements are issued.
• The strategy to acquire and hold Bitcoin introduces significant new risks, including price volatility, regulatory uncertainty, and potential for total loss due to theft or destruction, which is unusual for a pharmaceutical company.
• Promissory notes issued to various parties include acceleration clauses, meaning the full balance becomes due immediately if the company receives gross proceeds from any equity or debt financing, potentially creating liquidity pressure.

Risks

• The price of Bitcoin and other digital assets is highly volatile, which could significantly impact operating results and share price.
• The cryptocurrency treasury strategy is untested and may prove unsuccessful, materially adversely impacting financial condition.
• Digital assets are subject to significant legal, commercial, regulatory, and technical uncertainty, including potential reclassification as securities, which could force the company to cease operations or incur significant costs.
• Lack of legal recourse and insurance for digital assets increases the risk of total loss in the event of theft or destruction.
• The irreversibility of digital asset transactions exposes the company to risks of theft, loss, and human error.
• Changes in accounting treatment of cryptocurrency holdings (e.g., ASU 2023-08) could increase volatility of financial results and have adverse tax consequences.
• Cryptocurrency holdings are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity during market instability.
• Security breaches or cyberattacks on the company or its third-party service providers could lead to loss of cryptocurrency and material adverse effects.
• Custodially-held cryptocurrencies may become part of the custodian's insolvency estate in bankruptcy, leading to potential loss of assets.
• The emergence or growth of other digital assets (e.g., stablecoins, CBDCs) could negatively impact the price of cryptocurrencies held.
• Ongoing significant expenses and operating losses are expected for the foreseeable future, particularly from SP-102 development.
• Ability to generate product revenue and achieve profitability depends on successful development and commercialization of product candidates.
• Future funding requirements are uncertain and depend on many factors, including clinical trial progress, regulatory approvals, and manufacturing costs.
• Raising additional funds through equity or convertible debt could result in dilution or increased fixed payment obligations.
• Indebtedness could lead to restrictive covenants impairing competitiveness.

Future Outlook

New Semnur anticipates continued significant expenses and operating losses as it develops SP-102 and seeks regulatory approval. The company expects to incur increased expenses as a public entity and will explore various financing alternatives, including equity offerings, debt financings, and collaborations, to fund operations. The success of future development and regulatory approval for SP-102 is crucial. The company also plans to build up cryptocurrency reserves and implement treasury management strategies with Bitcoin.

Management Comments

• "Semnur is entering an exciting phase as the resources of the public capital markets will be available to enhance our business growth and enable us to continue to fulfill our mission to address patient non-opioid pain management needs." Henry Ji, Ph.D., Executive Chairperson of Semnur.
• "Our unique model continues to demonstrate the multiple ways in which we can unlock value for our stockholders." Henry Ji, Ph.D., Executive Chairperson of Semnur.
• "Our Semnur team and I are proud to continue our leadership in the creation of prescription non-opioid therapeutics addressing moderate to severe chronic radicular pain/sciatica." Jaisim Shah, Chief Executive Officer and President of Semnur.
• "As a public company, we aim to accelerate our mission to increase access to prescription non-opioid therapeutics by advancing our second Phase 3 clinical development in SP-102, and expanding public and private payer adoption." Jaisim Shah, Chief Executive Officer and President of Semnur.
• "I am very excited to work with Semnur on their next endeavor in the crypto space. The experience, forward-thinking, and the services that we have in the crypto space will prove to be a valuable asset to Semnur in various crypto currency projects." Dmitry Sheludko, CEO of Biconomy.com.

Industry Context

The biopharmaceutical industry is increasingly seeking non-opioid pain management solutions due to the ongoing opioid crisis and regulatory pressures. Semnur's focus on SP-102, a non-opioid treatment for sciatica with Fast Track status, aligns with this trend. However, the company's new strategy to incorporate Bitcoin into its treasury management is a highly unusual and speculative move for a pharmaceutical company, diverging significantly from traditional industry financial practices and introducing novel risks not typically associated with drug development firms.

Comparison to Industry Standards

• Semnur's focus on non-opioid pain therapies, particularly SP-102 for sciatica, aligns with a growing trend in the pharmaceutical industry to address the opioid crisis and develop safer pain management alternatives. Companies like Heron Therapeutics (HTBX) with ZYNRELEF and Pacira BioSciences (PCRX) with EXPAREL are also active in the non-opioid space, though their specific drug mechanisms and target indications may differ.
• The completion of a pivotal Phase 3 study for SP-102 with positive primary and secondary endpoints is a significant milestone, comparable to the late-stage development efforts of other specialty pharma companies aiming for FDA approval.
• The engagement of Biconomy.com for cryptocurrency strategies and the acceptance of Bitcoin for a $100 million equity investment is a highly unconventional and unprecedented financial strategy for a clinical-stage biopharmaceutical company. This deviates sharply from the conservative treasury management practices typically seen in the pharma sector, which usually prioritize stability and liquidity in traditional fiat currencies and low-risk investments. No direct comparable companies in the biopharma sector have adopted such a prominent cryptocurrency-based capital raise or treasury strategy.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings are pending or, to the knowledge of Semnur, threatened against or affecting Semnur, its common stock, or any of its officers or directors in their capacities as such, as of June 30, 2025.

Related Party Transactions

• Scilex Holding Company (SHC) converted $54,236,058 of outstanding intercompany indebtedness owed by Legacy Semnur to SHC into 5,423,606 shares of New Semnur Series A Preferred Stock and 542,361 shares of New Semnur Common Stock.
• SHC is the beneficial owner of a controlling interest in New Semnur, owning approximately 87.5% of common stock and 100% of Series A Preferred Stock post-Business Combination.
• New Semnur entered into employment agreements with Jaisim Shah (CEO & President) and Henry Ji, Ph.D. (Executive Chairperson), both of whom are also associated with Scilex.
• New Semnur will receive approximately $2.0 million of continued support from Scilex in the twelve months following the Business Combination, including clinical, manufacturing, and general/administrative support, under a Transition Services Agreement.
• Promissory notes were issued to Denali Capital Global Investments LLC (Sponsor), which is a related party, for $806,366.78.

Stakeholder Impact

• **Shareholders**: Existing shareholders of Denali and Legacy Semnur now hold shares in the combined public entity, Semnur Pharmaceuticals, Inc. The significant capital raise, including the Bitcoin investment, could provide necessary funding for operations and product development, but also introduces substantial new risks and potential volatility to the stock.
• **Employees**: Executive officers have new employment agreements with severance and change-in-control benefits, providing stability and incentives. The company's ability to continue as a going concern will directly impact all employees.
• **Customers/Patients**: The continued development of SP-102, a non-opioid pain therapy, could lead to new treatment options for patients suffering from chronic radicular pain/sciatica.
• **Creditors**: Existing related party debt has been converted to equity, improving the company's debt profile. However, new promissory notes have been issued, and their acceleration clauses could create future liquidity demands if certain financing events occur.
• **Regulatory Bodies**: The company's operations, particularly its new cryptocurrency strategy, may attract increased scrutiny from financial and securities regulators due to the novel and volatile nature of digital assets.

Next Steps

• File a resale registration statement for the Biconomy Shares under the Securities Act of 1933 within 90 days of the closing of the purchase and sale of the Biconomy Shares.
• Close the PIPE SPA transactions no later than the 14th business day following the closing of the Business Combination.
• Begin monthly installment payments for various promissory notes starting October 1, 2025.
• Continue efforts to develop and seek regulatory approval for SP-102, including advancing its second Phase 3 clinical development.
• Expand public and private payer adoption for non-opioid therapeutics.
• Implement cryptocurrency strategies, including crypto currency reserve build-up and treasury management, in collaboration with Biconomy.com.

Key Dates

Recommendation

The completion of the business combination and the substantial capital raise, including the $100 million Bitcoin investment, provide a critical lifeline for Semnur, especially given its accumulated deficit and going concern warning. The progress of SP-102 in Phase 3 trials is a positive for the core pharmaceutical business. However, the company's new strategy to hold and manage Bitcoin introduces an entirely new and significant layer of risk and volatility, which is highly unusual for a clinical-stage biopharmaceutical company. This speculative financial approach, combined with the ongoing operational losses and the inherent uncertainties of drug development, makes the stock a high-risk proposition. A 'hold' recommendation is appropriate for investors who are already exposed or are considering a speculative position, allowing time to assess how the cryptocurrency strategy impacts the company's financial stability and how the SP-102 program progresses, while acknowledging the substantial downside risks.

Keywords

Semnur Pharmaceuticals, Business Combination, Merger, Bitcoin Investment, Cryptocurrency Strategy, SP-102, SEMDEXA, Non-opioid Pain Therapy, SEC Filing, 8-K, Capital Raise, OTC Markets, Scilex Holding Company, Biopharmaceutical, Clinical Stage, Risk Factors, Promissory Notes, Debt Conversion, Corporate Governance